

Novavax to Participate in Jefferies London Healthcare Conference

November 10, 2023

GAITHERSBURG, Md., Nov. 10, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference.

Conference Details:

Fireside Chat

Date:	Wednesday, November 15, 2023
Time:	9:00 – 9:25 a.m. Greenwich Mean Time (GMT)
Location:	London
Moderator:	Roger Song, M.D., CFA, Equity Analyst
Novavax participants:	John C. Jacobs, President and Chief Executive Officer and Filip Dubovsky, M.D., President, Research & Development

Conference

Event:	Investor Meetings
Date:	Wednesday, November 15, 2023

Recordings

A replay of the recorded fireside session will be available through the Events & presentations page of the Company's website at ir.novavax.com for 45 days from the date of the conference.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and [LinkedIn](#) for more information.

Please visit novavax.com and [LinkedIn](#) for more information.

Contacts:

Investors

Erika Schultz
240-268-2022
ir@novavax.com

Media

Ali Chartan
240-720-7804
media@novavax.com

SOURCE NOVAVAX, INC